- Home
- CULP vs BTAI Comparison
CULP vs BTAI Comparison
Compare CULP & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CULP | BTAI |
|---|---|---|
| Founded | 1972 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 49.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CULP | BTAI |
|---|---|---|
| Price | $3.56 | $1.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 43.8K | ★ 456.8K |
| Earning Date | 12-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $204,919,000.00 | $752,000.00 |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $2.77 | $441.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.33 | $1.17 |
| 52 Week High | $5.94 | $9.26 |
Technical Indicators
Market Signals| Indicator | CULP | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 33.04 |
| Support Level | $3.33 | $1.66 |
| Resistance Level | $3.58 | $1.89 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 31.69 | 1.95 |
Price Performance
Historical ComparisonAbout CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.